CXCL14 as a potential marker for immunotherapy response prediction in renal cell carcinoma.

Authors:
Pan Q; Liu R; Zhang X; Cai L; Li Y and 4 more

Journal:
Ther Adv Med Oncol

Publication Year: 2023

DOI:
10.1177/17588359231217966

PMCID:
PMC10752123

PMID:
38152696

Journal Information

Full Title: Ther Adv Med Oncol

Abbreviation: Ther Adv Med Oncol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"The authors declare that there is no conflict of interest."

Evidence found in paper:

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the National Natural Science Foundation of China (Nos 82102988 and 81772483) and the Medical Research Foundation of Guangdong Province (No. A2022492)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025